DaVita's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 65.06.
DaVita's Days Inventory for the
three
months ended in Mar. 2026 was 5.88.
DaVita's Days Payable for the
three
months ended in Mar. 2026 was 27.01.
Therefore, DaVita's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 43.93.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
DaVita Cash Conversion Cycle Related Terms
DaVita Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for DaVita's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:DVA vs THC, EHC, ENSG: Cash Conversion Cycle Comparison
For the Medical Care Facilities subindustry, DaVita's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DaVita Cash Conversion Cycle vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DaVita's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where DaVita's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
DaVita's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DaVita (MEX:DVA) has a Cash Conversion Cycle of 43.93 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on DaVita and its competitors.
Is DaVita's Cash Conversion Cycle too high?
DaVita's current Cash Conversion Cycle is 43.93. The Healthcare Providers & Services industry median Cash Conversion Cycle is 18.10. DaVita's value of 43.93 is 142.7% above this industry median. Overall, DaVita has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does DaVita's Cash Conversion Cycle compare to THC and EHC?
DaVita's Cash Conversion Cycle of 43.93 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 18.10. DaVita's value of 43.93 is 142.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 18.10, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DaVita's current Cash Conversion Cycle of 43.93 is 142.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on DaVita and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 18.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DaVita's current Cash Conversion Cycle is 43.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaVita stock overvalued right now?
Based on GuruFocus' analysis, DaVita (MEX:DVA) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN2,564.33, compared to a current price of MXN3,358.09 — trading 31% above its estimated fair value. The current Cash Conversion Cycle is 43.93 and 142.7% above the Healthcare Providers & Services industry median of 18.10. DaVita's overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For DaVita (MEX:DVA), the current Cash Conversion Cycle is 43.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DaVita (MEX:DVA) Overvalued in 2026?
Based on GuruFocus' analysis, DaVita stock appears to be overvalued.
The current stock price of MXN3,358.09 is trading 31% above its estimated GF Value™ of MXN2,564.33.
GuruFocus considers DaVita to be Significantly Overvalued.
Key valuation signals for MEX:DVA:
Cash Conversion Cycle: 43.93
GF Value™: MXN2,564.33 vs. price of MXN3,358.09 (31% above fair value)
Industry Position: 142.7% above the Healthcare Providers & Services median
No single metric tells the full story. See the MEX:DVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
80GF Score
Get the complete analysis for MEX:DVA
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:DVA has been successfully added to your 
